EXSCEL

What is EXSCEL?

Cardiovascular outcomes for once-weekly exenatide in 14,752 adults with type 2 diabetes (Holman et al., NEJM 2017).

The primary outcome was neutral: exenatide did not significantly reduce MACE, which is why “GLP-1s protect the heart” is a claim about specific molecules rather than the class.

Related reading: EXSCEL: The Large Neutral Result

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where EXSCEL comes up on this site

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers